Back

Assessing the potential for precision medicine of glucose-lowering drugs in type 2 diabetes mellitus: a meta-regression analysis considering body weight variability from 120 randomized trials

25 August 2023 (07:30 - 18:30)
Organised by: Logo
Congress Presentation Part of: Partnering with patients through digital health Patient Engagement and Personalised Health ESC Professional Premium Access ESC Congress 2023 European Society of Cardiology

About the speaker

Photo
Doctor Kris Gregory Vargas

Ibbenbueren Hospital, Ibbenbueren (Germany)

7 More presentations in this session

Presentation thumbnail
Clinician-created video education for patients with atrial fibrillation: a randomised clinical trial
Doctor D. McIntyre (Sydney, AU)
Abstract Slides Video
Presentation thumbnail
Statin non-adherence findings from the My Experience of Taking Statin Medicines Questionnaire (mySTATINmed)
Doctor E. Kampouraki (Leeds, GB)
Abstract Slides Video
Presentation thumbnail
Quality of life after pulmonary veins isolation: outcomes from a digital follow-up program
Doctor R. Teixeira (Vila Nova de Gaia, PT)
Abstract Slides Video
Presentation thumbnail
Conversational artificial intelligence intervention to support patients with atrial fibrillation: process evaluation of a randomised controlled trial
Ms R. Trivedi (Sydney, AU)
Abstract Slides Video
Presentation thumbnail
Knowledge and unmet needs of patients with atrial fibrillation in China: a nationwide cross-sectional survey
Professor C. Jiang (Beijing, CN)
Abstract Slides

Access the full session

Session thumbnail
Partnering with patients through digital health

The Event

Event poster

ESC Congress 2023

25 August - 28 August 2023
You may be interested in
thumbnail
Congress Session
When the diet does not work: pharmacological options for obesity
thumbnail
Congress Presentation
Parallel improvement of arterial stiffness with weight loss following intensification of antidiabetic treatment
thumbnail
Congress Presentation
Real-world use of oral semaglutide in adults with type 2 diabetes: the PIONEER REAL Switzerland multicentre, prospective, observational study

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources